
This deal brings together two companies with a shared vision for more connected, personalized healthcare, and it arrives just six weeks after Oura pulled its planned IPO.
Oura spent much of 2026 preparing to go public. The smart ring maker set terms to raise up to $2.2 billion on the Nasdaq at $40 to $44 per share, a range that would have valued the company at more than $15 billion. Then, on September 29, Oura postponed the offering, citing uncertainty in the IPO market.
Other hypotheses for the IPO pivot include: concern that the valuation was too rich for a business still weighted toward hardware, a deal structure in which roughly 73% of the shares on offer came from existing shareholders rather than new capital for the company, and the looming threat of larger wearables players such as Apple. Underneath all three sits the same question: is Oura a ring maker, or a health platform?
Counsel Health seems to be Oura’s answer. Founded in 2023 by Dr. Muthu Alagappan, a Stanford-trained physician and former AI researcher, Counsel pairs medical AI with in-house, board-certified physicians. Members start with an AI chat that draws on medical records, clinical guidelines and continuous biometric data, and can bring in a physician within minutes for diagnoses, prescriptions and referrals. Counsel has raised an estimated $36 million, including a $25 million Series A led by Andreessen Horowitz and GV, and has been available inside the Oura app since earlier this year. After the acquisition, Counsel will continue serving health plans, health systems and employers, extending its reach beyond Oura’s members.

Counsel adds recurring clinical services to a hardware-heavy business, opens enterprise channels with payers and employers, and gives Oura a way to act on the data it collects. Oura frames the deal as expanding its addressable market and increasing member lifetime value, backed by a record quarter: revenue rose 153% year over year to $533 million, and fiscal 2026 revenue reached roughly $1.75 billion. Women’s health sits at the center of that strategy. Women are now the majority of Oura’s new members, the company launched a women’s health AI model in February, and Counsel’s specialty care plans include reproductive health. If Oura returns to the public markets, the pitch will now include clinical care. It will be a care platform built on continuous data, with women among its most engaged users.
The deal is also a meaningful data point for digital health exits. After years in which only a handful of digital health companies reached the public markets, acquisitions have become the dominant exit path. Consolidation has long been the expected endgame for the sector, and the Counsel deal is a prime example. Counsel is a pure digital health company, built on software and virtual care, selling for roughly 17 times its estimated capital raised about three years after founding, to a buyer that sees it as core to its strategy. For digital health founders, the deal shows that consolidation can reward companies that make a larger platform more valuable.
Some early-stage players in AI-enabled, digital women’s and sexual health:
Defiant (Series A) — Virtual cancer care clinic that speeds up expert diagnosis and treatment for patients (Amboy Street portfolio company)
Alloy (Series B) — Telehealth platform delivering menopause care from menopause-trained clinicians, plus treatments for women over 40 (Amboy Street portfolio company)
Allswell (Seed) — Insurance-covered virtual behavioral health clinic built for the LGBTQ+ community (Amboy Street portfolio company)
We look forward to keeping you updated as we invest in the $1T women's health and sexual health space.


